Cencora, Inc. $COR Shares Sold by State of Alaska Department of Revenue

State of Alaska Department of Revenue decreased its position in shares of Cencora, Inc. (NYSE:COR) by 34.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 24,338 shares of the company’s stock after selling 12,839 shares during the quarter. State of Alaska Department of Revenue’s holdings in Cencora were worth $8,219,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently modified their holdings of COR. United Bank boosted its holdings in shares of Cencora by 4.5% during the second quarter. United Bank now owns 7,032 shares of the company’s stock valued at $2,109,000 after acquiring an additional 305 shares during the period. Nebula Research & Development LLC acquired a new stake in Cencora in the second quarter worth about $595,000. Treasurer of the State of North Carolina lifted its holdings in Cencora by 7.9% in the second quarter. Treasurer of the State of North Carolina now owns 85,534 shares of the company’s stock worth $25,647,000 after purchasing an additional 6,244 shares during the period. Diversify Advisory Services LLC lifted its holdings in Cencora by 94.1% in the second quarter. Diversify Advisory Services LLC now owns 2,585 shares of the company’s stock worth $747,000 after purchasing an additional 1,253 shares during the period. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main lifted its holdings in Cencora by 26.0% in the second quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 73,452 shares of the company’s stock worth $22,025,000 after purchasing an additional 15,154 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other Cencora news, CEO Robert P. Mauch sold 5,096 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total value of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at approximately $23,669,713.98. This represents a 7.10% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.38% of the company’s stock.

Cencora Price Performance

Shares of NYSE COR opened at $318.96 on Tuesday. Cencora, Inc. has a twelve month low of $271.00 and a twelve month high of $377.54. The company has a current ratio of 0.92, a quick ratio of 0.51 and a debt-to-equity ratio of 3.62. The company has a market capitalization of $62.05 billion, a price-to-earnings ratio of 38.34, a PEG ratio of 1.50 and a beta of 0.72. The firm has a 50-day moving average of $344.46 and a two-hundred day moving average of $342.97.

Cencora (NYSE:COR) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating analysts’ consensus estimates of $4.04 by $0.04. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The company had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. During the same period in the prior year, the company earned $3.73 EPS. Cencora’s revenue was up 5.5% on a year-over-year basis. As a group, analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were issued a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio is presently 28.85%.

Wall Street Analyst Weigh In

Several research firms recently weighed in on COR. Evercore set a $360.00 price objective on shares of Cencora in a report on Wednesday, April 8th. JPMorgan Chase & Co. upped their price objective on shares of Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a report on Tuesday, February 10th. Morgan Stanley set a $380.00 price objective on shares of Cencora in a report on Tuesday, March 17th. Bank of America reduced their price objective on shares of Cencora from $380.00 to $360.00 and set a “neutral” rating for the company in a report on Monday, January 5th. Finally, Barclays upped their price objective on shares of Cencora from $400.00 to $425.00 and gave the stock an “overweight” rating in a report on Friday, February 13th. Twelve equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to MarketBeat, Cencora currently has a consensus rating of “Moderate Buy” and a consensus target price of $398.17.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.